PSP Research
Latest statistics and disclosures from PSP Research's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SGOV, XBI, SERA, DFTX, TYRA, and represent 79.95% of PSP Research's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$36M), SERA, DFTX, IRON, AGIO, AXSM, ARDX, RARE, GLUE, CMPS.
- Started 21 new stock positions in ELVN, ORKA, DFTX, TNGX, XBI, AXSM, NTLA, GLUE, ERAS, KALV. EWTX, CMPS, CMPX, IRON, AGIO, SERA, TRVI, ARDX, RARE, SMMT, ORIC.
- Reduced shares in these 10 stocks: DNTH, TVTX, , CGON, BLTE, APLS, TERN, RVMD, CNTA, SYRE.
- Sold out of its positions in ALMS, APLS, ACLX, ARWR, BEAM, BLTE, BMRN, CNTA, CGON, DNLI.
- PSP Research was a net buyer of stock by $26M.
- PSP Research has $141M in assets under management (AUM), dropping by 23.52%.
- Central Index Key (CIK): 0002106939
Tip: Access up to 7 years of quarterly data
Positions held by PSP Research consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for PSP Research
PSP Research holds 79 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ishares Tr 0-3 Mnth Treasry (SGOV) | 49.9 | $71M | 700k | 100.66 |
|
|
| Spdr Series Trust State Street Spd (XBI) | 25.7 | $36M | NEW | 285k | 127.73 |
|
| Sera Prognostics Class A Com (SERA) | 3.4 | $4.9M | NEW | 2.4M | 2.03 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.5 | $658k | NEW | 35k | 18.90 |
|
| Tyra Biosciences (TYRA) | 0.4 | $613k | -26% | 16k | 38.30 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.4 | $572k | -3% | 2.5k | 228.73 |
|
| Pharvaris N V (PHVS) | 0.4 | $565k | -2% | 20k | 28.25 |
|
| Cytokinetics Com New (CYTK) | 0.4 | $547k | 8.3k | 65.91 |
|
|
| Royalty Pharma Shs Class A (RPRX) | 0.4 | $528k | -20% | 11k | 47.97 |
|
| Kymera Therapeutics (KYMR) | 0.4 | $525k | 6.3k | 83.29 |
|
|
| Halozyme Therapeutics (HALO) | 0.4 | $519k | 8.0k | 64.63 |
|
|
| Exelixis (EXEL) | 0.4 | $512k | 12k | 42.89 |
|
|
| Disc Medicine (IRON) | 0.4 | $512k | NEW | 8.0k | 63.94 |
|
| Ionis Pharmaceuticals (IONS) | 0.4 | $511k | 6.8k | 75.09 |
|
|
| Agios Pharmaceuticals (AGIO) | 0.4 | $508k | NEW | 15k | 33.83 |
|
| Neurocrine Biosciences (NBIX) | 0.4 | $507k | +3% | 3.8k | 131.74 |
|
| Incyte Corporation (INCY) | 0.4 | $499k | 5.3k | 94.12 |
|
|
| Tarsus Pharmaceuticals (TARS) | 0.3 | $491k | +7% | 7.0k | 70.15 |
|
| Viking Therapeutics (VKTX) | 0.3 | $488k | 15k | 32.54 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 0.3 | $485k | +11% | 1.5k | 330.87 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.3 | $483k | -24% | 1.5k | 322.19 |
|
| Axsome Therapeutics (AXSM) | 0.3 | $481k | NEW | 2.8k | 169.02 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.3 | $480k | 15k | 32.01 |
|
|
| Ardelyx (ARDX) | 0.3 | $479k | NEW | 80k | 5.99 |
|
| Immunovant (IMVT) | 0.3 | $477k | -5% | 19k | 24.84 |
|
| Argenx Se Sponsored Adr (ARGX) | 0.3 | $468k | 641.00 | 730.25 |
|
|
| Syndax Pharmaceuticals (SNDX) | 0.3 | $467k | -19% | 20k | 23.36 |
|
| Inhibrx Biosciences (INBX) | 0.3 | $466k | +8% | 6.9k | 67.23 |
|
| Arcutis Biotherapeutics (ARQT) | 0.3 | $464k | +5% | 20k | 23.56 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $463k | NEW | 22k | 20.95 |
|
| Mirum Pharmaceuticals (MIRM) | 0.3 | $462k | -27% | 5.0k | 92.38 |
|
| Cogent Biosciences (COGT) | 0.3 | $462k | -9% | 12k | 38.49 |
|
| Monte Rosa Therapeutics (GLUE) | 0.3 | $461k | NEW | 28k | 16.45 |
|
| Immunocore Hldgs Ads (IMCR) | 0.3 | $457k | +4% | 15k | 30.15 |
|
| Crispr Therapeutics Namen Akt (CRSP) | 0.3 | $452k | 9.5k | 47.57 |
|
|
| Bridgebio Pharma (BBIO) | 0.3 | $446k | -15% | 6.0k | 74.26 |
|
| Nurix Therapeutics (NRIX) | 0.3 | $445k | 29k | 15.50 |
|
|
| Aurinia Pharmaceuticals (AUPH) | 0.3 | $445k | -11% | 30k | 14.82 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.3 | $440k | 20k | 22.26 |
|
|
| Rapport Therapeutics (RAPP) | 0.3 | $438k | -20% | 14k | 31.29 |
|
| Immunome (IMNM) | 0.3 | $437k | -20% | 20k | 21.87 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.3 | $433k | -28% | 9.0k | 48.15 |
|
| Tg Therapeutics (TGTX) | 0.3 | $432k | -26% | 13k | 33.22 |
|
| Dianthus Therapeutics (DNTH) | 0.3 | $420k | -60% | 5.0k | 83.92 |
|
| Celldex Therapeutics Com New (CLDX) | 0.3 | $412k | -36% | 13k | 31.72 |
|
| Ptc Therapeutics I (PTCT) | 0.3 | $409k | -14% | 6.0k | 68.13 |
|
| Vera Therapeutics Cl A (VERA) | 0.3 | $402k | 10k | 40.23 |
|
|
| Harmony Biosciences Hldgs In (HRMY) | 0.3 | $400k | 14k | 28.01 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 0.3 | $400k | -2% | 11k | 36.32 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $393k | NEW | 71k | 5.53 |
|
| Stoke Therapeutics (STOK) | 0.3 | $391k | -27% | 12k | 32.56 |
|
| Kodiak Sciences (KOD) | 0.3 | $381k | -48% | 10k | 38.12 |
|
| Dyne Therapeutics (DYN) | 0.3 | $363k | -7% | 20k | 18.13 |
|
| Trevi Therapeutics (TRVI) | 0.3 | $358k | NEW | 30k | 11.93 |
|
| Intellia Therapeutics (NTLA) | 0.2 | $345k | NEW | 27k | 12.82 |
|
| Protagonist Therapeutics (PTGX) | 0.2 | $316k | -50% | 3.0k | 105.40 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.2 | $314k | -32% | 600.00 | 523.47 |
|
| Supernus Pharmaceuticals (SUPN) | 0.2 | $310k | -44% | 6.0k | 51.69 |
|
| Tango Therapeutics (TNGX) | 0.2 | $301k | NEW | 14k | 20.92 |
|
| Erasca (ERAS) | 0.2 | $280k | NEW | 17k | 16.18 |
|
| Enliven Therapeutics (ELVN) | 0.2 | $274k | NEW | 7.0k | 39.20 |
|
| Spyre Therapeutics Com New (SYRE) | 0.2 | $260k | -67% | 5.2k | 50.44 |
|
| Zymeworks Del (ZYME) | 0.2 | $250k | -50% | 10k | 25.04 |
|
| Xenon Pharmaceuticals (XENE) | 0.2 | $244k | -64% | 4.2k | 58.15 |
|
| Oruka Therapeutics (ORKA) | 0.2 | $244k | NEW | 5.0k | 49.05 |
|
| Celcuity (CELC) | 0.2 | $228k | -61% | 2.0k | 114.14 |
|
| Kalvista Pharmaceuticals (KALV) | 0.2 | $217k | NEW | 11k | 20.13 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.2 | $217k | -50% | 12k | 18.09 |
|
| Alkermes SHS (ALKS) | 0.2 | $212k | -68% | 6.0k | 35.36 |
|
| Apogee Therapeutics (APGE) | 0.1 | $210k | -64% | 2.5k | 84.17 |
|
| United Therapeutics Corporation (UTHR) | 0.1 | $208k | -67% | 350.00 | 592.98 |
|
| Edgewise Therapeutics (EWTX) | 0.1 | $205k | NEW | 6.5k | 31.50 |
|
| Summit Therapeutics (SMMT) | 0.1 | $194k | NEW | 10k | 18.96 |
|
| Oric Pharmaceuticals (ORIC) | 0.1 | $165k | NEW | 13k | 12.67 |
|
| Compass Therapeutics (CMPX) | 0.1 | $159k | NEW | 30k | 5.29 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.1 | $151k | -75% | 11k | 13.90 |
|
| Olema Pharmaceuticals (OLMA) | 0.1 | $149k | -47% | 10k | 14.91 |
|
| Eyepoint Com New (EYPT) | 0.1 | $129k | -66% | 10k | 12.89 |
|
| Ocular Therapeutix (OCUL) | 0.1 | $127k | -64% | 15k | 8.47 |
|
Past Filings by PSP Research
SEC 13F filings are viewable for PSP Research going back to 2025
- PSP Research 2026 Q1 filed April 17, 2026
- PSP Research 2025 Q4 filed Feb. 6, 2026